e14549 Background: To describe pts with pancreatic cancer and determine whether comorbidity indices predict survival. Methods: In an IRB-approved protocol, we reviewed the records of patients (pts) diagnosed with pancreatic cancer at a VA Medical Center from January 1999 to October 2009. Records were reviewed for demographic, clinical, pathological data, ECOG performance status (PS), Veteran status, treatment and survival. Comorbidity was accessed with three comorbidity indices: the Charlson Comorbidity Index (CCI), the Kaplan-Feinstein Index (KFI), and Cumulative Illness Rating Scale (CIRS). Cox survival analyses were performed. Results: There were 52 pts with a median (M) age of 63yo (45-89). 27 pts were Caucasian, 22 pts were African American and 3 pts of Hispanic descent. Out of the 52 pts, 27 were Vietnam era veterans. The median (M) PS was 1 (0-4) . The M BMI was 23.4 kg/m2 (16.13-32). The M WBC was 9.75 (2.1-37.3), M hemoglobin (Hgb) 10.95 g/dl (7.1-15.4), M AST 59 U/L (20-498), M albumin (Alb) 3.1 g/dl (1.7-20), M alkaline phosphatase (ALP) 267.5 U/L (42-1234), M lactate dehydrogenase (LDH) 184.5 IU/L (53-2590), and M CEA 6.2 ng/ml (1.2-188.64). The M CCI was 3.35 (1.3-12.9), M KFI 2 (0-3), M CIRS15 3 (0-9), M CIRS16 6 (0-13), M CIRS17 2 (0-4) and M survival was 109 days (2-1968). In the univariate survival analysis, WBC (p<0.047), AST (p<0.032), Alb (p<0.043), LDH (p<0.057), and CEA (p<0.022) and treatment modalities were significant predictors of survival. In the multivariate analysis only PS (p<.033) and stage (p<0.004) were independent predictors. Vietnam and non-Vietnam patients differed by age of diagnosis (p<0.001), by stage distribution (p<0.04), and survival (p<0.001) and by predictors of survival. By univariate analysis, for Vietnam, vets, PS, LDH and albumin were significant and for Non Vietnam, WBC and AST were significant. Conclusions: Comorbidity indices were not predictors of survival. Interesting differences are seen between Vietnam and non-Vietnam veterans with pancreatic cancer that should be studied further. Partially supported by the New Jersey Commission for Cancer Research.